MX2017004828A - Composicion oftalmica que comprende ciclosporina y trehalosa. - Google Patents
Composicion oftalmica que comprende ciclosporina y trehalosa.Info
- Publication number
- MX2017004828A MX2017004828A MX2017004828A MX2017004828A MX2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A
- Authority
- MX
- Mexico
- Prior art keywords
- ophthalmic composition
- cyclosporine
- trehalose
- ophthalmoxerosis
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición oftálmica que comprende ciclosporina y trehalosa como componentes efectivos, un método para producir el mismo, un método para prevenir, mejorar o tratar el fallo causado por oftalmoxerosis administrando el mismo, y un uso para el mismo. La composición oftálmica de acuerdo con la presente invención tiene una combinación de efectos superiores sobre la oftalmoxerosis, que puede ser causada por diversos factores tales como aire seco, inflamación, conservantes, etc., y se coloca en una variedad de estados o condiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140141089A KR101587412B1 (ko) | 2014-10-17 | 2014-10-17 | 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물 |
PCT/KR2015/011048 WO2016060532A1 (ko) | 2014-10-17 | 2015-10-19 | 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004828A true MX2017004828A (es) | 2017-07-20 |
Family
ID=55308741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004828A MX2017004828A (es) | 2014-10-17 | 2015-10-19 | Composicion oftalmica que comprende ciclosporina y trehalosa. |
Country Status (14)
Country | Link |
---|---|
US (1) | US10039803B2 (es) |
EP (1) | EP3213763B1 (es) |
JP (1) | JP6611803B2 (es) |
KR (1) | KR101587412B1 (es) |
CN (1) | CN106999543B (es) |
AU (1) | AU2015331089B2 (es) |
BR (1) | BR112017007813A2 (es) |
ES (1) | ES2773641T3 (es) |
MX (1) | MX2017004828A (es) |
PH (1) | PH12017500615B1 (es) |
RU (1) | RU2700927C2 (es) |
SA (1) | SA517381318B1 (es) |
SG (1) | SG11201704695WA (es) |
WO (1) | WO2016060532A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3280412T (pt) * | 2015-04-09 | 2019-11-15 | Laboratori Baldacci Spa | Ácido pirrolidona carboxílico (pca) para utilização oftálmica |
KR20180030323A (ko) * | 2016-09-13 | 2018-03-22 | 주식회사 코아팜바이오 | 사이클로스포린의 안구필름 제형 |
KR102268319B1 (ko) * | 2016-12-29 | 2021-06-23 | (주)휴온스 | 지속성 점안제 조성물 |
EP3412276A3 (de) * | 2017-06-09 | 2019-07-17 | Omnivision GmbH | Zusammensetzung zur behandlung des trockenen auges |
WO2019025986A1 (en) * | 2017-08-02 | 2019-02-07 | Shilpa Medicare Limited | OPHTHALMIC COMPOSITIONS OF CYCLOSPORINE |
CN113069556B (zh) * | 2021-04-12 | 2022-04-08 | 青岛大学附属医院 | 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法 |
CN113262235B (zh) * | 2021-04-25 | 2022-10-21 | 自然资源部第三海洋研究所 | 新琼寡糖在治疗眼科疾病方面的新用途 |
WO2023229332A1 (ko) * | 2022-05-24 | 2023-11-30 | 줄리아 연구소 주식회사 | 트레할로스를 포함하는 망막 질환 또는 퇴행성 뇌 질환의 예방, 개선 또는 치료용 건강식품 조성물 및 약학적 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
AU781975B2 (en) | 2000-09-14 | 2005-06-23 | Hayashibara Co., Ltd | Pharmaceutical composition for ophthalmic use |
JP4982643B2 (ja) * | 2000-09-14 | 2012-07-25 | 株式会社林原 | 眼科用医薬組成物 |
DE102006051512A1 (de) * | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
US20080146497A1 (en) * | 2006-07-25 | 2008-06-19 | Graham Richard S | Cyclosporin Compositions |
CN101049504B (zh) * | 2007-04-05 | 2010-05-19 | 广州立恩生物科技有限公司 | 一种脂质体药物载体及其制备方法 |
AU2008310956B2 (en) * | 2007-10-08 | 2014-08-07 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
US9402812B2 (en) * | 2009-09-23 | 2016-08-02 | Indu JAVERI | Methods for the preparation of liposomes |
JP5918275B2 (ja) * | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
US20130029919A1 (en) | 2011-07-26 | 2013-01-31 | Allergan, Inc. | Two part formulation system for opthalmic delivery |
KR101211902B1 (ko) * | 2012-04-30 | 2012-12-13 | 주식회사 휴온스 | 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물 |
EP2887923B1 (en) * | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
KR101492447B1 (ko) * | 2013-05-20 | 2015-02-23 | 주식회사태준제약 | 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법 |
WO2015013330A2 (en) * | 2013-07-22 | 2015-01-29 | Kineta One, Llc | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof |
AU2015289387B2 (en) * | 2014-07-18 | 2020-10-22 | Allergan, Inc. | Suspension compositions of cyclosporin A for subconjunctival and periocular injection |
-
2014
- 2014-10-17 KR KR1020140141089A patent/KR101587412B1/ko active IP Right Grant
-
2015
- 2015-10-19 CN CN201580056326.9A patent/CN106999543B/zh active Active
- 2015-10-19 RU RU2017116974A patent/RU2700927C2/ru active
- 2015-10-19 EP EP15850677.4A patent/EP3213763B1/en active Active
- 2015-10-19 MX MX2017004828A patent/MX2017004828A/es unknown
- 2015-10-19 ES ES15850677T patent/ES2773641T3/es active Active
- 2015-10-19 SG SG11201704695WA patent/SG11201704695WA/en unknown
- 2015-10-19 AU AU2015331089A patent/AU2015331089B2/en active Active
- 2015-10-19 JP JP2017520527A patent/JP6611803B2/ja active Active
- 2015-10-19 US US15/519,497 patent/US10039803B2/en active Active
- 2015-10-19 BR BR112017007813A patent/BR112017007813A2/pt active Search and Examination
- 2015-10-19 WO PCT/KR2015/011048 patent/WO2016060532A1/ko active Application Filing
-
2017
- 2017-04-03 PH PH12017500615A patent/PH12017500615B1/en unknown
- 2017-04-16 SA SA517381318A patent/SA517381318B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017531022A (ja) | 2017-10-19 |
SA517381318B1 (ar) | 2020-09-09 |
AU2015331089A1 (en) | 2017-06-08 |
EP3213763B1 (en) | 2020-01-08 |
RU2017116974A (ru) | 2018-11-21 |
RU2017116974A3 (es) | 2019-04-17 |
WO2016060532A1 (ko) | 2016-04-21 |
US20170224766A1 (en) | 2017-08-10 |
EP3213763A1 (en) | 2017-09-06 |
ES2773641T3 (es) | 2020-07-13 |
PH12017500615A1 (en) | 2017-09-04 |
KR101587412B1 (ko) | 2016-01-21 |
JP6611803B2 (ja) | 2019-11-27 |
RU2700927C2 (ru) | 2019-09-24 |
CN106999543B (zh) | 2021-01-05 |
CN106999543A (zh) | 2017-08-01 |
BR112017007813A2 (pt) | 2017-12-19 |
US10039803B2 (en) | 2018-08-07 |
PH12017500615B1 (en) | 2017-09-04 |
EP3213763A4 (en) | 2018-07-18 |
SG11201704695WA (en) | 2017-07-28 |
AU2015331089B2 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500615A1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
MX2018005829A (es) | Composiciones para tratar el cabello. | |
WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
MY169328A (en) | Compositions for the treatment of dry eye | |
CA2900779C (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
WO2015127134A3 (en) | Complement component c5 antibodies | |
WO2016094834A3 (en) | A method for treating a complement mediated disorder caused by an infectious agent in a patient | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
WO2016007540A3 (en) | Compositions and methods for treating dengue virus infection | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
MX2015008310A (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
PH12017501022B1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
WO2016134257A8 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
TW201613628A (en) | Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
WO2016135456A3 (en) | A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy | |
EP3496738C0 (en) | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HEART DAMAGE |